ERCC1 Is a Predictive Biomarker for Non-small Cell Lung Cancer But Is Antibody-dependent

Background/Aim: To predict the efficacy of platinum-containing chemotherapy, ERCC1 expression levels were investigated. Studies have shown changes in performance anti-ERCC1 antibodies; therefore, predicting chemotherapy by immunohistochemical assessment is controversial. Patients and Methods: Twenty-eight patients who received underwent computed tomography evaluation 6-9 weeks after therapy initiation retrospectively identified. The tumor samples evaluated 2012 2018 using latest antibodies available at those times. Results: In 2012, H-score was significantly higher with disease progression than without (p=0.019). Although same trend 2018, there some inconsistent results between samples. Conclusion: tumors showing low had a better control rate on chemotherapy. However, since antibody changed over time, standardized technology to evaluate needed.